{"id":12473,"date":"2025-07-30T18:31:41","date_gmt":"2025-07-30T16:31:41","guid":{"rendered":"https:\/\/www.kliinikum.ee\/yhendlabor\/?page_id=12473"},"modified":"2025-12-11T17:19:40","modified_gmt":"2025-12-11T15:19:40","slug":"infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg","status":"publish","type":"page","link":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\/","title":{"rendered":"Infliksimab ja infliksimabi-vastaste antikehade hulk seerumis (S-Infliximab, S-Infliximab Ab QN)"},"content":{"rendered":"\n<p><em>Kliinilise keemia ja laboratoorse hematoloogia osakond<\/em><\/p>\n\n\n\n<p><strong>Infliksimab <\/strong>on bioloogilise ravimina kasutatav rekombinantne inimese monoklonaalne antikeha. See seostub spetsiifiliselt TNF\u03b1-ga, neutraliseerides TNF\u03b1 toime\u00a0 ja p\u00e4rssides seekaudu p\u00f5letikulist reaktsiooni. Infliksimabi kasutatakse nt reumatoidartriidi, psoriaatilise artriidi, ank\u00fcloseeriva spond\u00fcliidi, p\u00f5letikuliste soolehaiguste, m\u00e4dase higin\u00e4\u00e4rmep\u00f5letiku \u00a0jt ravis. Infliksimabi baaskontsentratsioon seerumis korreleerub h\u00e4sti ravi efektiivsusega.<\/p>\n\n\n\n<p>Ravi k\u00e4igus v\u00f5ivad m\u00f5nel patsiendil tekkida infliksimabi-vastased antikehad, mist\u00f5ttu ravimi kontsentratsioon seerumis ja raviefekt v\u00e4henevad. Samuti v\u00f5ivad antikehad p\u00f5hjustada lokaalseid k\u00f5rvaltoimeid.<\/p>\n\n\n\n<p>Lisaks s\u00f5ltub ravimi kontsentratsioon seerumis veel ravimi doosist ja manustamise sagedusest, haiguse fenot\u00fc\u00fcbist ja aktiivsusastmest, teistest samaaegselt manustatavatest ravimitest ja farmakogeneetilistest faktoritest.<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Uuritav materjal, selle v\u00f5tmine, saatmine ja s\u00e4ilitamine<\/strong><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><em>Oluline on v\u00f5tta veri uuringuks vahetult enne j\u00e4rgmist ravimi annust (baaskontsentratsioon)!<\/em><\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table width=\"100%\"><tbody><tr><td width=\"1%\"><\/td><td width=\"15%\"><strong>Katsuti<\/strong><\/td><td width=\"84%\">Geeli ja h\u00fc\u00fcbimisaktivaatoriga katsuti (punane kollase r\u00f5ngaga kork v\u00f5i kollane kork)<\/td><\/tr><tr><td><\/td><td><strong>S\u00e4ilivus<\/strong><\/td><td>Seerum toatemperatuuril kolm p\u00e4eva, +4 \u00b0C kaheksa p\u00e4eva <\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Anal\u00fc\u00fcsi tegemise aeg:<\/strong> kord n\u00e4dalas<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Anal\u00fc\u00fcsimeetod: <\/strong>kemoluminestsents-immuunmeetod (CLIA)<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Referentsv\u00e4\u00e4rtused<\/strong><\/p>\n\n\n\n<p>Infliksimabi terapeutiline kontsentratsioon s\u00f5ltub patsiendi diagnoosist, haiguse aktiivsuse astmest, ravi faasist (induktsioonifaas, s\u00e4ilitusravi) ja v\u00f5ib erinevate kirjandusallikate p\u00f5hjal olla vahemikus &gt;5 mg\/L kuni 10 (15) mg\/L.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><em>Infliksimabi-vastased antikehad<\/em><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table width=\"100%\"><tbody><tr><td width=\"1%\"><\/td><td width=\"30%\"><strong>< 10 \u00b5g\/L<\/strong><\/td><td width=\"69%\">negatiivne<\/td><\/tr><tr><td><\/td><td><strong>\u2265 10 \u00b5g\/L<\/strong><\/td><td>positiivne<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"has-medium-font-size\"><strong>N\u00e4idustus ja kliiniline t\u00e4hendus<\/strong><\/p>\n\n\n\n<p>Infliksimab-ravi j\u00e4lgimine (nii proaktiivne j\u00e4lgimine kui v\u00e4henenud raviefekti v\u00f5i selle puudumise p\u00f5hjuste selgitamine).<\/p>\n\n\n\n<p>Kui infliksimabi kontsentratsioon on subterapeutiline, kuid antikehasid ei esine, v\u00f5ib parema raviefekti saavutamiseks olla abi ravimi doosi t\u00f5stmisest v\u00f5i manustamisintervalli l\u00fchendamisest. Antikehade olemasolul ravimannuse suurendamine efekti ei anna ja tuleb m\u00f5elda alternatiivsetele ravivalikutele.<\/p>\n\n\n\n<p>Terapeutilisest vahemikust k\u00f5rgem kontsentratsioon ei suurenda raviefekti ega anna t\u00e4iendavat kasu.<\/p>\n\n\n\n<p>Katrin Reimand<\/p>\n\n\n\n<p>Koostatud 29.08.2025<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kliinilise keemia ja laboratoorse hematoloogia osakond Infliksimab on bioloogilise ravimina kasutatav rekombinantne inimese monoklonaalne antikeha. See seostub spetsiifiliselt TNF\u03b1-ga, neutraliseerides TNF\u03b1 toime\u00a0 ja p\u00e4rssides seekaudu p\u00f5letikulist reaktsiooni. Infliksimabi kasutatakse nt reumatoidartriidi, psoriaatilise artriidi, ank\u00fcloseeriva spond\u00fcliidi, p\u00f5letikuliste soolehaiguste, m\u00e4dase higin\u00e4\u00e4rmep\u00f5letiku \u00a0jt ravis. Infliksimabi baaskontsentratsioon seerumis korreleerub h\u00e4sti ravi efektiivsusega. Ravi k\u00e4igus v\u00f5ivad m\u00f5nel patsiendil tekkida infliksimabi-vastased [&hellip;]<\/p>\n","protected":false},"author":38,"featured_media":0,"parent":7301,"menu_order":9,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-12473","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Infliksimab ja infliksimabi-vastaste antikehade hulk seerumis (S-Infliximab, S-Infliximab Ab QN) - \u00dchendlabor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Infliksimab ja infliksimabi-vastaste antikehade hulk seerumis (S-Infliximab, S-Infliximab Ab QN) - \u00dchendlabor\" \/>\n<meta property=\"og:description\" content=\"Kliinilise keemia ja laboratoorse hematoloogia osakond Infliksimab on bioloogilise ravimina kasutatav rekombinantne inimese monoklonaalne antikeha. See seostub spetsiifiliselt TNF\u03b1-ga, neutraliseerides TNF\u03b1 toime\u00a0 ja p\u00e4rssides seekaudu p\u00f5letikulist reaktsiooni. Infliksimabi kasutatakse nt reumatoidartriidi, psoriaatilise artriidi, ank\u00fcloseeriva spond\u00fcliidi, p\u00f5letikuliste soolehaiguste, m\u00e4dase higin\u00e4\u00e4rmep\u00f5letiku \u00a0jt ravis. Infliksimabi baaskontsentratsioon seerumis korreleerub h\u00e4sti ravi efektiivsusega. Ravi k\u00e4igus v\u00f5ivad m\u00f5nel patsiendil tekkida infliksimabi-vastased [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00dchendlabor\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-11T15:19:40+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutit\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\\\/\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\\\/\",\"name\":\"Infliksimab ja infliksimabi-vastaste antikehade hulk seerumis (S-Infliximab, S-Infliximab Ab QN) - \u00dchendlabor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\"},\"datePublished\":\"2025-07-30T16:31:41+00:00\",\"dateModified\":\"2025-12-11T15:19:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\\\/#breadcrumb\"},\"inLanguage\":\"et\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00e4siraamat\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ravimiseire uuringud\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Infliksimab ja infliksimabi-vastaste antikehade hulk seerumis (S-Infliximab, S-Infliximab Ab QN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\",\"name\":\"\u00dchendlabor\",\"description\":\"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"et\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Infliksimab ja infliksimabi-vastaste antikehade hulk seerumis (S-Infliximab, S-Infliximab Ab QN) - \u00dchendlabor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\/","og_locale":"et_EE","og_type":"article","og_title":"Infliksimab ja infliksimabi-vastaste antikehade hulk seerumis (S-Infliximab, S-Infliximab Ab QN) - \u00dchendlabor","og_description":"Kliinilise keemia ja laboratoorse hematoloogia osakond Infliksimab on bioloogilise ravimina kasutatav rekombinantne inimese monoklonaalne antikeha. See seostub spetsiifiliselt TNF\u03b1-ga, neutraliseerides TNF\u03b1 toime\u00a0 ja p\u00e4rssides seekaudu p\u00f5letikulist reaktsiooni. Infliksimabi kasutatakse nt reumatoidartriidi, psoriaatilise artriidi, ank\u00fcloseeriva spond\u00fcliidi, p\u00f5letikuliste soolehaiguste, m\u00e4dase higin\u00e4\u00e4rmep\u00f5letiku \u00a0jt ravis. Infliksimabi baaskontsentratsioon seerumis korreleerub h\u00e4sti ravi efektiivsusega. Ravi k\u00e4igus v\u00f5ivad m\u00f5nel patsiendil tekkida infliksimabi-vastased [&hellip;]","og_url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\/","og_site_name":"\u00dchendlabor","article_modified_time":"2025-12-11T15:19:40+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutit"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\/","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\/","name":"Infliksimab ja infliksimabi-vastaste antikehade hulk seerumis (S-Infliximab, S-Infliximab Ab QN) - \u00dchendlabor","isPartOf":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website"},"datePublished":"2025-07-30T16:31:41+00:00","dateModified":"2025-12-11T15:19:40+00:00","breadcrumb":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\/#breadcrumb"},"inLanguage":"et","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/infliximab-seerumis-ja-infliximabi-vastane-igg-seerumis-s-infliximab-s-infliximab-igg\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/"},{"@type":"ListItem","position":2,"name":"K\u00e4siraamat","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/"},{"@type":"ListItem","position":3,"name":"Ravimiseire uuringud","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/"},{"@type":"ListItem","position":4,"name":"Infliksimab ja infliksimabi-vastaste antikehade hulk seerumis (S-Infliximab, S-Infliximab Ab QN)"}]},{"@type":"WebSite","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/","name":"\u00dchendlabor","description":"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kliinikum.ee\/yhendlabor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"et"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"Kadi Siigur","author_link":"https:\/\/www.kliinikum.ee\/yhendlabor\/author\/kadisi\/"},"uagb_comment_info":0,"uagb_excerpt":"Kliinilise keemia ja laboratoorse hematoloogia osakond Infliksimab on bioloogilise ravimina kasutatav rekombinantne inimese monoklonaalne antikeha. See seostub spetsiifiliselt TNF\u03b1-ga, neutraliseerides TNF\u03b1 toime\u00a0 ja p\u00e4rssides seekaudu p\u00f5letikulist reaktsiooni. Infliksimabi kasutatakse nt reumatoidartriidi, psoriaatilise artriidi, ank\u00fcloseeriva spond\u00fcliidi, p\u00f5letikuliste soolehaiguste, m\u00e4dase higin\u00e4\u00e4rmep\u00f5letiku \u00a0jt ravis. Infliksimabi baaskontsentratsioon seerumis korreleerub h\u00e4sti ravi efektiivsusega. Ravi k\u00e4igus v\u00f5ivad m\u00f5nel patsiendil tekkida infliksimabi-vastased&hellip;","_links":{"self":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/12473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/comments?post=12473"}],"version-history":[{"count":0,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/12473\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/7301"}],"wp:attachment":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/media?parent=12473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}